AEON Biopharma, Inc. — Form S-1
Filed July 8, 2026 · analyzed by the Registration Agent
S-1
▼ Likely negative
significance 72/100
What the filing says
AEON Biopharma (market cap ~$8.7M) filed Form S-1 on July 8, 2026 to raise ~$11M gross (~$11M net) via: 17.5M common shares at $0.7151/share, pre-funded warrants, and milestone warrants (2-year and 5-year). As of March 31, 2026: accumulated deficit $482.6M; stockholders' deficit $(16.8)M; going-concern doubt through Q3 2026. NYSE American non-compliance: stockholders' equity deficit of ~$55M (vs. $4M minimum required). Company targeting biosimilar pathway for ABP-450 (botulinum toxin) and expects to complete analytical program in 2026, pending FDA Type 2B meeting.
Why this rating
Fundraising at 4.3x cash needed immediately addresses going-concern crisis; but massive dilution (67% post-offering), NYSE delisting risk, and accumulated $483M deficit make this survival-focused, not growth. Significant for company size despite small dollars.
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.